by Scott Harwood | Oct 25, 2023
The U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is...
by Scott Harwood | Oct 25, 2023
Joseph Mikhael, MD, Chief Medical Officer at the International Myeloma Foundation talks about the M-POWER program. Transcription: At the International Myeloma Foundation, it’s a privilege for me to work there, one of the greatest...
by Scott Harwood | Oct 11, 2023
The U.S. Food and Drug Administration (FDA) is taking significant steps to expedite the development of novel drug and biological products for rare diseases. Support for Clinical Trials Advancing Rare Disease Therapeutics (START) aims to provide increased support and...
by Scott Harwood | Mar 13, 2023
Bernie Williams, former New York Yankee baseball player and current jazz musician, discusses the need for physicians to be aware of early signs and symptoms of various interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). IPF is a chronic,...
by Scott Harwood | Dec 19, 2022
Rebecca Silbermann, MD, MMS, of the Knight Cancer Translational Oncology Program, Oregon Health & Science University, discusses patient reported outcomes from the phase 2 GRIFFIN trial, assessing daratumumab plus lenalidomide, bortezomib, and dexamethasone...
